Idiopathic Short Stature

8
Pipeline Programs
7
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
5
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
3 programs
2
1
Somatotropin growth hormone recombinant humanPhase 41 trial
Aromatase InhibitorPhase 3
GenotropinPhase 31 trial
Active Trials
NCT00396097Completed316Est. Aug 2012
NCT00458263Completed21Est. May 2011
Ipsen
IpsenChina - Tianjin
1 program
1
Nutropin [SomatropinPhase 41 trial
Active Trials
NCT01438801Withdrawn0Est. May 2013
Novartis
NovartisBASEL, Switzerland
1 program
1
Aromatase InhibitorPhase 31 trial
Active Trials
NCT01248416Completed76Est. Sep 2016
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Aromatase InhibitorPhase 3
M&
Merck & Co.RAHWAY, NJ
1 program
1
Saizen®Phase 31 trial
Active Trials
NCT01746862CompletedEst. Mar 2015
BioMarin Pharmaceutical
1 program
1
Vosoritide InjectionPhase 21 trial
Active Trials
NCT06382155Recruiting100Est. Dec 2036
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
No treatment is givenN/A1 trial
Active Trials
NCT05894876Terminated43Est. Mar 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
IpsenNutropin [Somatropin
PfizerSomatotropin growth hormone recombinant human
Merck & Co.Saizen®
NovartisAromatase Inhibitor
PfizerGenotropin
BioMarin PharmaceuticalVosoritide Injection
Novo NordiskNo treatment is given

Clinical Trials (7)

Total enrollment: 556 patients across 7 trials

NCT01438801IpsenNutropin [Somatropin

Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)

Start: May 2013Est. completion: May 20130
Phase 4Withdrawn
NCT00458263PfizerSomatotropin growth hormone recombinant human

Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

Start: Apr 2006Est. completion: May 201121 patients
Phase 4Completed
NCT01746862Merck & Co.Saizen®

A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)

Start: Dec 2012Est. completion: Mar 2015
Phase 3Completed
NCT01248416NovartisAromatase Inhibitor

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

Start: Nov 2010Est. completion: Sep 201676 patients
Phase 3Completed
NCT00396097PfizerGenotropin

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

Start: Dec 2006Est. completion: Aug 2012316 patients
Phase 3Completed
NCT06382155BioMarin PharmaceuticalVosoritide Injection

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Start: Oct 2024Est. completion: Dec 2036100 patients
Phase 2Recruiting
NCT05894876Novo NordiskNo treatment is given

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

Start: Apr 2024Est. completion: Mar 202543 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 556 patients
7 companies competing in this space